Anti-PD-1 antibodies and uses thereof
US12404331B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 17, 2020 |
| Grant date | Sep 2, 2025 |
| Priority date | — |
| Expiry date | Oct 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to isolated monoclonal antibodies or antigen-binding fragments thereof that specifically bind to PD-1 and block the interaction between PD-1 and PD-L1/PD-L2. The disclosure also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies, portions of fusion proteins or bispecific antibodies. Nucleic acid molecules encoding the antibodies, hybridomas, and methods for expressing antibodies are also provided. Pharmaceutical compositions comprising the antibodies are also provided. This disclosure also provides use of these antibodies to enhance T-cell function and upregulate cell-mediated immune responses for the treatment and prevention of various diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.